

# EBiSC PROJECT SUMMARY

## EBiSC – European Bank for induced pluripotent Stem Cells



EBiSC, the European Bank for induced pluripotent Stem Cells (iPSC), is designed to address the increasing demand by researchers for **quality-controlled, disease-relevant research grade iPSC lines, data and cell services**. Its goal is to demonstrate an operational banking and distribution service of iPSC lines and to establish subsequently for Europe a centralised, **not-for-profit bank** providing all qualified users with access to scalable, cost-efficient and customised products.

EBiSC is **public-private partnership** project supported by the Innovative Medicines Initiative (IMI) and pharmaceutical companies who are members of the European Federation of Pharmaceutical Industries and Associations (EFPIA) and represents all stakeholders from tissue donors to clinical and academic iPSC researchers and industrial users. Led by Pfizer Ltd. and managed by Roslin Cells Sciences Ltd., the consortium of 27 organisations comprises 8 active participant iPSC Centres with clinical and patient networks, a global leader in industrial iPSC supply, international experts in iPSC science, biobanking, bioengineering and regenerative medicine, and scholars in law and ethics.

The **EBiC central facility** operated by Roslin Cell Science is located at the Babraham Research Campus (Cambridge, UK) and undertakes cell expansion, Quality Control and characterisation. The European Cell Culture Collection (ECACC) of Public Health England (Department of Health, UK) coordinates cell line distribution. The Fraunhofer IBMT (Saarbrücken, Germany) provides a comprehensive operational back up facility.

The **EBiSC Catalogue**, which has been officially launched on 23 March 2016 at <https://cells.ebisc.org/>, is a collection of human iPSC cells which are made available to academic and commercial researchers for use in disease modelling and other forms of preclinical research. Currently, the EBiSC catalogue comprises 147 iPSC lines. The initial collection has been generated from a wide range of donors representing specific disease backgrounds and healthy controls which have been made and deposited by EBiSC partner labs and a number of external organisations. This currently includes neurodegenerative diseases (Frontotemporal Dementia, Motor Neurone Disease (ALS) - and Huntington's Disease), eye and heart diseases, and lines from healthy control donors for age and sex matching. New cell lines are constantly being added to the catalogue through collaborations with international partner research consortia as well as new cell lines generated within the EBiSC consortium. The EBiSC catalogue will soon see a large number of Parkinson's and Alzheimer's Disease lines being introduced together with lines for diabetes and cardiovascular research as well as muscular dystrophies and neuropathic pain.

External users, both customers and cell line depositors, can access information linked to the iPSC lines proposed in the catalogue via an **Information Management System (IMS)** established by EBiSC.

Access the EBiSC Cell Line Catalogue at <https://cells.ebisc.org>

More information at [www.ebisc.eu](http://www.ebisc.eu)

Contact: [ebisc@eurtd.com](mailto:ebisc@eurtd.com)